GOVX Geovax Labs Inc
11,727
$1.65
$0.09
(5.77%)
| Watchers | 11,727 |
| 52-Wk Low | $1.38 |
| 52-Wk High | $11.54 |
| Market Cap | $3.6M |
| Volume | 2,493.00 |
| 52-Wk High | $11.54 |
| 52-Wk Low | $1.38 |
GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 VaccineGlobe Newswire • about 1 month ago
Presentation Made During the 24th Annual World Vaccine Congress ATLANTA, GA, April 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...
Share to Feed
ATLANTA, GA, March 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
ATLANTA, GA, March 12, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
Manufacturing Process for Phase 3 and Commercial Production Being Developed for GeoVax MVA-Based Vaccines ATLANTA, GA, March 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire GeoVax Labs, Inc...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on GeoVax Labs (GOVX Research Report), Madrigal Pharmaceuticals...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Progress across the pipeline in multiple clinical trials, includingPhase 2 program of GEO-CM04S1, next-generation Covid-19 vaccine, andmulticenter Phase 1/2 study of Gedeptin , targeting advanced...
GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company...
ATLANTA, GA, Feb. 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...